XUANZHUBIO-B (02575) announced that its self-developed innovative drug, Palociclib Tablets (brand name: Xuan Yuening®), has been included in the National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance (2025 Edition) for the first time. The 2025 NRDL will officially take effect on January 1, 2026.

The successful inclusion in the NRDL is expected to enhance the affordability and accessibility of Xuan Yuening® for patients, further driving market promotion and expanding sales. This development is anticipated to have a positive long-term impact on the company's operations.

XUANZHUBIO-B will actively collaborate to facilitate the implementation of the reimbursement policy, continue advancing hospital access, expand core markets, and broaden coverage to improve patient access to the medication.